PDCD1 and endometrial cancer: In recent years, data from clinical studies on immune checkpoint inhibition in EC have demonstrated the efficacy of PD-1 inhibitors in a subgroup of advanced PD-L1-positive endometrial cancer patients who failed previous multi-line treatments [32].